BRMS1 and central nervous system cancer: In this study, our data first demonstrated that BRMS1 is significantly decreased in clinical glioma tissues and glioma cells compared to tumor adjacent normal brain tissue and NHA by Immunohistochemical and Western blot technique (Fig. 1A–G).